Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influvac 2009/2010 Immunogenicity and Safety Study
NCT00881842Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Jun 2009
- Primary completion
- Jul 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of inactivated influenza vaccine (surface antigen) in influenza, sponsored by Abbott Laboratories. Primary endpoints: Hemagglutination Inhibition titers at 3 weeks, Seroprotection rate at 3 weeks and 4 more. Started Jun 2009; status: completed.
02
Drugs
inactivated influenza vaccine (surface antigen)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00881842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00881842.